SK Chemicals Launches Low-Dose Triple Combination Hypertension Drug "Telamclo"

Combination of Telmisartan, Amlodipine, and Chlorthalidone
Formulated at Half the Standard Dose

SK Chemicals has expanded its product lineup by launching a low-dose triple combination therapy for hypertension.

Photo of Telamclo tablets, a triple combination drug for hypertension launched by SK Chemicals. Photo by SK Chemicals

On April 16, SK Chemicals announced the release of "Telamclo," a hypertension treatment that combines telmisartan, amlodipine, and chlorthalidone.

Telamclo is a low-dose triple combination medication, with each component provided at approximately half the standard dose. It contains 20mg of telmisartan, 2.5mg of amlodipine, and 6.25mg of chlorthalidone. The drug was developed in collaboration with Yuhan Corporation.

Recent trends in hypertension treatment are shifting from simply increasing the dose of a single medication to combining drugs with different mechanisms of action from the outset. The guidelines of the Korean Society of Hypertension also recommend the use of combination therapies for patients whose blood pressure is not controlled with monotherapy.

Each component works to lower blood pressure through a different mechanism. Telmisartan inhibits vascular constriction, amlodipine relaxes blood vessels, and chlorthalidone controls blood pressure by promoting the excretion of sodium and water.

In a clinical trial conducted at 28 domestic institutions with approximately 300 participants, the group treated with Telamclo showed an average reduction of 19.43 mmHg in systolic blood pressure after 8 weeks compared to baseline. This decrease was greater than that observed with telmisartan 40mg monotherapy, which showed a reduction of 15.65 mmHg. The blood pressure control rate was about 70%.

This medication is designed to be taken once daily for greater convenience in administration.

According to the market research firm IQVIA, the domestic market for hypertension treatments grew to approximately 2.3 trillion won in 2025. The number of hypertension patients in Korea is estimated to be around 12.6 million.

Park Hyunseon, Head of Pharmaceutical Business at SK Chemicals, said, "With the launch of Telamclo, we have expanded our portfolio from single-agent and dual-combination therapies to include a triple-combination therapy, thereby broadening the range of options available for hypertension treatment."

This content was produced with the assistance of AI translation services.